ArticleThe Journal of experimental medicine2018
JDP2: An oncogenic bZIP transcription factor in T cell acute lymphoblastic leukemia.
Open access · hybridAbstract read
In one paragraph
Article in The Journal of experimental medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
2.8field-weighted citation impact, top 10% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 30 citations in OpenAlex.
- Advances and Challenges in RAS Signaling Targeted Therapy in Leukemia.Molecular cancer therapeutics · 2025Review
- New insights into coordinated regulation of AHR promoter transcription; molecular mechanisms and therapeutic targets.International journal of biological sciences · 2025Review
- IRF2BP2 counteracts the ATF7/JDP2 AP-1 heterodimer to prevent inflammatory overactivation in acute myeloid leukemia (AML) cells.Nucleic acids research · 2024Article
- Thyroid cancer prognostic biomarker ARL4A and its relationship with immune infiltration.International journal of clinical and experimental pathology · 2024Article
- Opposing effects of KDM6A and JDP2 on glucocorticoid sensitivity in T-ALL.Blood advances · 2023Article
- Therapeutic targeting of LCK tyrosine kinase and mTOR signaling in T-cell acute lymphoblastic leukemia.Blood · 2022Article
- DEK modulates both expression and alternative splicing of cancer‑related genes.Oncology reports · 2022Article
- Network based systems biology approach to identify diseasome and comorbidity associations of Systemic Sclerosis with cancers.Heliyon · 2022Article
- Development and validation of a chromatin regulator prognostic signature in colon adenocarcinoma.Frontiers in genetics · 2022Article
- Modeling the developmental origins of pediatric cancer to improve patient outcomes.Disease models & mechanisms · 2021Review
- Loss of glucocorticoid receptor expression mediates in vivo dexamethasone resistance in T-cell acute lymphoblastic leukemia.Leukemia · 2020Article
- Pediatric Cancer Models in Zebrafish.Trends in cancer · 2020Review
- Article
- Tackling Acute Lymphoblastic Leukemia-One Fish at a Time.International journal of molecular sciences · 2019Review
- Zebrafish and Medaka: Two Teleost Models of T-Cell and Thymic Development.International journal of molecular sciences · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
27 authors at 8 institutions in 5 countries.
Marc R MansourDepartment of Haematology, University College London Cancer Institute, London, England, UK m.mansour@ucl.ac.uk.ORCID 0000-0001-6835-3791
Shuning HeDepartment of Pediatric Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.
Zhaodong LiDepartment of Pediatric Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.
Riadh LobbardiMolecular Pathology and Cancer Center, Massachusetts General Hospital, Boston, MA.
Brian J AbrahamWhitehead Institute for Biomedical Research, Cambridge, MA.ORCID 0000-0001-8085-3027
Clemens HugDepartment of Pediatric Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.
Sunniyat RahmanDepartment of Haematology, University College London Cancer Institute, London, England, UK.
Theresa E LeonDepartment of Haematology, University College London Cancer Institute, London, England, UK.ORCID 0000-0002-0958-5995
You-Yi KuangHeilongjiang River Fisheries Research Institute of Chinese Academy of Fishery Sciences, Harbin, China.ORCID 0000-0003-4053-9353
Mark W ZimmermanDepartment of Pediatric Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.
Traci BlonquistDepartment of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, MA.ORCID 0000-0003-1346-988X
Evisa GjiniDepartment of Pediatric Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.
Alejandro GutierrezStem Cell Program and Division of Hematology/Oncology, Boston Children's Hospital and Dana Farber Cancer Institute, Howard Hughes Medical Institute, Harvard Medical School, Boston, MA.ORCID 0000-0002-0249-9007
Qin TangMolecular Pathology and Cancer Center, Massachusetts General Hospital, Boston, MA.
Laura Garcia-PerezDepartment of Immunohematology, Leiden University Medical Center, Leiden, Netherlands.
Karin Pike-OverzetDepartment of Immunohematology, Leiden University Medical Center, Leiden, Netherlands.
Lars AndersWhitehead Institute for Biomedical Research, Cambridge, MA.
Alla BerezovskayaDepartment of Pediatric Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.
Yi ZhouHarvard Stem Cell Institute, Stem Cell and Regenerative Biology Department, Harvard University, Cambridge, MA.ORCID 0000-0003-0935-1635
Leonard I ZonHarvard Stem Cell Institute, Stem Cell and Regenerative Biology Department, Harvard University, Cambridge, MA.ORCID 0000-0003-0860-926X
Donna NeubergDepartment of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, MA.ORCID 0000-0003-2566-3145
Adele K FieldingDepartment of Haematology, University College London Cancer Institute, London, England, UK.
Frank J T StaalDepartment of Immunohematology, Leiden University Medical Center, Leiden, Netherlands.ORCID 0000-0003-1588-8519
David M LangenauMolecular Pathology and Cancer Center, Massachusetts General Hospital, Boston, MA.ORCID 0000-0001-6664-8318
Takaomi SandaCancer Science Institute of Singapore, National University of Singapore, Singapore.
Richard A YoungWhitehead Institute for Biomedical Research, Cambridge, MA.
A Thomas LookDepartment of Pediatric Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA thomas_look@dfci.harvard.edu.ORCID 0000-0001-7851-8617
Harvard University · USBoston Children's Hospital · USLeiden University Medical Center · NLLondon Cancer · GBWhitehead Institute for Biomedical Research · USDana-Farber Cancer Institute · USChinese Academy of Fishery Sciences · CNNational University of Singapore · SG
Funding
COG FOREIGN ACCRUALU10CA098543 · NCI · NATIONAL CHILDHOOD CANCER FOUNDATION · PI ADAMSON, PETER C. · 2003 to 2013
$335.5MChildren's Oncology Group Statistics &Data Center GrantU10CA098413 · NCI · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI DEVIDAS, MEENAKSHI · 2003 to 2013
$67.5MZebrafish Screens for Genetic Modifiers and Human Application in T-ALLP01CA068484 · NCI · DANA-FARBER CANCER INSTITUTE · PI KUTOK, JEFFERY LORNE · 1995 to 2010
$31.9MTranscriptional mechanisms and melanomaP01CA163222 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI Kai W Wucherpfennig · 2013 to 2026
$25.3MThe Molecular Function of D-cyclins in T-ALLP01CA109901 · NCI · DANA-FARBER CANCER INSTITUTE · PI YOUNG, RICHARD · 2004 to 2014
$19.6MSupport for Human Specimen Banking in NCI-Supported Cancer Clinical TrialsU24CA114766 · NCI · RESEARCH INST NATIONWIDE CHILDREN'S HOSP · PI RAMIREZ MILAN, NILSA DEL CARMEN · 2005 to 2014
$14.5MCancer Biology in the ZebrafishR01CA103846 · NCI · CHILDREN'S HOSPITAL BOSTON · PI ZON, LEONARD IRA · 2003 to 2022
$7.5MMechanisms and Vulnerabilities of Aberrant Transcriptional Enhancers in CancerR35CA210064 · NCI · DANA-FARBER CANCER INST · PI LOOK, A. THOMAS · 2016 to 2022
$7.3MEMBRYONIC HEMATOPOIESISR01HL048801 · NHLBI · CHILDREN'S HOSPITAL BOSTON · PI ZON, LEONARD IRA · 1992 to 2016
$5.7MOncogenic pathways and therapeutic targets in T cell acute lymphoblastic leukemiaR01CA211734 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI LANGENAU, DAVID MICHAEL · 2017 to 2021
$1.9MDiscovery of New Targets and Pathways for T-ALL TherapyR01CA176746 · NCI · DANA-FARBER CANCER INST · PI LOOK, A. THOMAS · 2012 to 2015
$1.5MDiscovery and Targeting of Apoptosis Resistance Mechanisms in High-Risk T-ALLR21CA167124 · NCI · BOSTON CHILDREN'S HOSPITAL · PI GUTIERREZ, ALEJANDRO · 2012 to 2013
$403kCancer Research UK 21019Cancer Research UK 9609Department of HealthHoward Hughes Medical InstituteNCI NIH HHS P01 CA068484NCI NIH HHS P01 CA109901NCI NIH HHS P01 CA163222NCI NIH HHS R01 CA103846NCI NIH HHS R01 CA176746NCI NIH HHS R01 CA211734NCI NIH HHS R21 CA167124NCI NIH HHS R35 CA210064NCI NIH HHS U10 CA098413NCI NIH HHS U10 CA098543NCI NIH HHS U24 CA114766NHLBI NIH HHS R01 HL048801
Abstract
A substantial subset of patients with T cell acute lymphoblastic leukemia (T-ALL) develops resistance to steroids and succumbs to their disease.
Indexed as
OncogenesAnimalsApoptosisBase SequenceCell ProliferationCell SurvivalChild, PreschoolDexamethasoneDisease Models, AnimalEnhancer Elements, GeneticGene Expression Regulation, LeukemicGlucocorticoidsHumansInfantMiceMutagenesis, InsertionalDexamethasoneGlucocorticoidsJDP2 protein, humanMCL1 protein, humanMyeloid Cell Leukemia Sequence 1 ProteinProto-Oncogene Proteins c-mycRepressor ProteinsZebrafish Proteins
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.